2021 ACCP Virtual Journal Club Webinar-December | Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics-On Demand
2021 ACCP Virtual Journal Club Webinar: Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics - On Demand
On-demand webinar recording: December 8, 2021 to December 8, 2024
Why is this article important to your practice?
Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF mutations. Cobimetinib is extensively metabolized in liver; thus, patients with hepatic impairment (HI) might have increased cobimetinib exposure. By attending this educational activity, you will learn about the impact of HI on the pharmacokinetics (PK) and safety of cobimetinib.
Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.